Summary
The Eighth Circuit reviewed a Freedom of Information Act dispute concerning the Drug Enforcement Administration's withholding of oxycodone distribution data under Exemption 4 for confidential commercial information. The court upheld the application of Exemption 4 but held that the district court failed to make the required express finding regarding segregability of non-exempt information. The judgment was reversed and remanded, including the rulings on declaratory and injunctive relief and attorney fees.
Topics
Practice areas
Questions Presented
- Whether the DEA adequately established that ARCOS report 1 and four company-specific oxycodone-distribution spreadsheets were confidential commercial information exempt from disclosure under FOIA Exemption 4.
- Whether the DEA demonstrated that the withheld documents contained no reasonably segregable nonexempt information.
- Whether the district court was required to make an express finding on FOIA segregability.
- Whether the denials of declaratory and injunctive relief and attorney fees should be reversed and remanded in light of the segregability error.
Holdings
- The DEA adequately established that the withheld records contained confidential commercial information whose disclosure was likely to cause substantial competitive harm, and the district court did not err in holding the information subject to Exemption 4.
- A district court must make an express finding on FOIA segregability in every case, and the district court erred by failing to do so.
- The DEA failed to show with reasonable specificity why the withheld documents could not be further segregated, so the segregability issue had to be remanded.
Key quotations
“In every case, the district court must make an express finding on the issue of segregability.” (-6-)
“DEA, relying solely on the Declaration, does not show “with reasonable specificity why documents withheld pursuant to a valid exemption cannot be further segregated.”” (-7-)
Factual background
Madel requested DEA records concerning oxycodone distributions in Georgia by five private companies and seven ARCOS reports. The DEA produced several ARCOS reports but withheld ARCOS report 1 and four company-specific spreadsheets under FOIA Exemption 4, asserting that disclosure could reveal market shares, inventories, sales trends, and customer information and cause competitive harm. The DEA withheld the documents in their entirety without establishing that all reasonably segregable nonexempt information had been disclosed.
Procedural history
Madel submitted two FOIA requests to the DEA seeking information concerning oxycodone transactions and ARCOS reports. After the DEA produced some records but withheld five documents under FOIA Exemption 4, Madel sued in the United States District Court for the District of Minnesota. The district court granted summary judgment to the DEA, found the withheld information exempt, dismissed declaratory and injunctive relief as moot, and denied attorney fees. The Eighth Circuit reversed and remanded because the district court failed to make an express segregability finding and the DEA had not shown with reasonable specificity that no nonexempt information could be segregated.
Remand instructions
The district court must make an express finding on segregability and conduct further proceedings consistent with the opinion. The denials of declaratory and injunctive relief and attorney fees are also reversed and remanded.